Introduction to Critical Pharmacy Issues in Cancer and Thrombosis Prophylaxis: Pharmacologic Foundations of Patient Care
Program Co-Chair: Samuel Z. Goldhaber, MD

Pharmacy-Based DVT Risk Profiling in Cancer Patients: What Landmark Trials Teach the HSP About the Need for Pharmacologic Prophylaxis in the Setting of Malignancy: What Works? What Doesn’t?
Samuel Z. Goldhaber

ASCO and NCCN Guidelines for DVT Prophylaxis in Cancer Patients: The Hospital Pharmacist’s Perspective—Cost, Quality of Care, and Guideline Adherence: A Real World Pharmacy-Based Perspective
John Fanikos, RPh, MBA

Pharmacologic Prophylaxis of DVT in Special Patient Populations: Dosing, Risks, and Strategies for Patients with Cancer and Associated Comorbid Conditions
Program Co-Chair: Edith Nutescu, PharmD, FCCP

Identifying Cancer Patients at Risk for DVT: Implementation of a Hospital-Based ALERT System for the Clinical Pharmacist and Medical Staff: A Collaborative Approach to Pharmacologic Thromboprophylaxis
Karen Fiumara, PharmD

QUESTION AND ANSWER SESSION
Faculty Panel